Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Urine Biopsy As Dynamic Biomarker To Enhance Clinical Staging Of Bladder Cancer In Radical Cystectomy Candidates.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Urine Biopsy As Dynamic Biomarker To Enhance Clinical Staging Of Bladder Cancer In Radical Cystectomy Candidates.

    • Related Experiment Video

    Cell-Free DNA Integrity Analysis in Urine Samples
    07:58

    Cell-Free DNA Integrity Analysis in Urine Samples

    Published on: January 5, 2017

    13.8K

    Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.

    Uttam Satyal1, Henkel Valentine1, David Liu2,3

    • 1Fox Chase Cancer Center, Philadelphia, PA.

    JCO Precision Oncology
    |June 12, 2024

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    This study developed a urine-based molecular assay to accurately identify bladder cancer patients who responded completely to neoadjuvant chemotherapy (NAC). This molecular assay can help avoid unnecessary radical cystectomy (RC) in complete responders.

    More Related Videos

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    14.7K
    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    14.7K

    Related Experiment Videos

    Cell-Free DNA Integrity Analysis in Urine Samples
    07:58

    Cell-Free DNA Integrity Analysis in Urine Samples

    Published on: January 5, 2017

    13.8K
    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    14.7K
    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    14.7K

    Area of Science:

    • Urology
    • Oncology
    • Molecular Diagnostics

    Background:

    • Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard for muscle-invasive bladder cancer.
    • Accurate restaging after NAC is crucial to identify complete responders who may avoid RC.
    • Current clinical restaging methods lack sufficient accuracy.

    Purpose of the Study:

    • To develop and validate a next-generation sequencing (NGS)-based molecular assay using urine.
    • To enhance the clinical staging accuracy of bladder cancer patients undergoing NAC and RC.
    • To identify complete responders to NAC for potential avoidance of RC.

    Main Methods:

    • Urine samples were collected prospectively from two cohorts of bladder cancer patients undergoing RC.
    • An NGS-based assay was developed to detect mutations in urine (M_U).
    • The assay was benchmarked and validated for its correlation with residual disease status post-NAC.

    Main Results:

    • Urine-derived mutations (M_U) were representative of tissue-derived mutations (M_T).
    • Residual M_U status strongly correlated with residual disease in the validation cohort (p=0.0092).
    • The assay demonstrated 82% overall accuracy, with 91% sensitivity and 86% positive predictive value.

    Conclusions:

    • Urine molecular testing (M_U) can accurately reflect tumor status (M_T).
    • This urine-based assay can enhance clinical staging for urothelial carcinoma.
    • Urine biopsy shows promise for identifying complete NAC response, potentially enabling safe avoidance of RC.